Get the Stockscreener App
1,280.34
4.46%
54.61
Pre-market:
1274.50
-5.84
-0.46%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,280.34, with a volume of 4.43M.
It is up +4.46% in the last 24 hours and up +8.59% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,225.73
Open:
$1245.81
24h Volume:
4.43M
Relative Volume:
1.50
Market Cap:
$1.14T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
46.09
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+4.92%
1M Performance:
+8.59%
6M Performance:
+25.13%
1Y Performance:
+82.07%
1-Day Range:
$1,240.54
$1,292.65
1-Week Range:
$1,163.50
$1,292.65
52-Week Range:
$685.15
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,280.34 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.41 | 653.35B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.97 | 457.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.20 | 333.49B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.31 | 293.76B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly and Company $LLY Shares Bought by AlTi Global Inc. - MarketBeat
Upper Macungie planners endorse Eli Lilly plan for manufacturing campus - wfmz.com
Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough? - Mitrade
Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading 4.5% HigherHere's Why - MarketBeat
Eli Lilly and Co (LLY) Stock Up 4.5% and Still Undervalued -- GF Score: 96/100 - GuruFocus
Could Eli Lilly Be Worth More Than SpaceX by the End of 2026? - Yahoo Finance
LLY Looks 15.4% Undervalued on GF Value™ Amid New Vaccine Partne - GuruFocus
Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases - PR Newswire
Eli Lilly Shares Approach High as 60% Volume Surge Offsets 13% Price Fall - TechStock²
Eli Lilly hits $1 trillion valuation, with stro... - Pluang
Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold? - 24/7 Wall St.
Lilly Stock Rises on Alzheimer Deal: Retatrutide Moat Still Not Fully Priced - Tech Times
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Stock Forecast: The Market is Sleeping on Eli Lilly’s Next $1 Trillion Opportunity - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month HighStill a Buy? - MarketBeat
Eli Lilly and Co Stock (LLY) Moved Up by 5.18% on Aug 19: What Investors Need To Know - TradingKey
Eli Lilly (NYSE:LLY): Is Its Valuation Story Getting Stronger? - Kalkine Media
Eli Lilly stock hits all-time high at 1249.95 USD By Investing.com - Investing.com Nigeria
Why is Eli Lilly stock surging today? - Investing.com
Lilly Turns Lifelong Struggle with Weight Into Story of Hope in ‘A Life Covered’ - Little Black Book | LBBOnline
Inside Eli Lilly’s Pre-Launch Push to Police the Retatrutide Market - thefashionlaw.com
Eli Lilly (NYSE:LLY) Expands Neuroscience Reach With New Drug Deals - Kalkine Media
Lilly Is Trailing In Obesity Pills; How Long Will That Last? - Investor's Business Daily
CNBC Final Trades: Netflix, Eli Lilly, Elanco Animal Health & MoreNetflix (NASDAQ:NFLX), Eli Lilly (NY - Benzinga
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Janney Montgomery Scott LLC Has $357.98 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Parr Mcknight Wealth Management Group LLC Acquires 1,702 Shares of Eli Lilly and Company $LLY - MarketBeat
HighTower Advisors LLC Sells 4,236 Shares of Eli Lilly and Company $LLY - MarketBeat
Convergence Financial LLC Purchases 4,147 Shares of Eli Lilly and Company $LLY - MarketBeat
Fifth Third Bancorp Sells 212,702 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Bought by BLB&B Advisors LLC - MarketBeat
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly? - BioSpace
UnitedHealth Group (UNH) vs. Eli Lilly and Company (LLY): Which Healthcare Stock Offers the Better Dividend? - Yahoo Finance
Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals - Yahoo Finance
Eli Lilly (NYSE:LLY): What Could Shift the Healthcare Story? - Kalkine Media
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.7%What's Next? - MarketBeat
Eli Lilly and Company (NYSE:LLY) EVP Sells $7,638,150.00 in Stock - MarketBeat
Eli Lilly and Co(LLY.US) Officer Sells US$7.64 Million in Common Stock - moomoo.com
How Lilly, Stock Of The Day, Is Regaining On Its Chief Rival - Investor's Business Daily
Why Eli Lilly (LLY) Stock Is Up Today - StockStory
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Eli Lilly and Co Stock (LLY) Moved Up by 3.19% on Aug 18: What Signal Does It Send? - TradingKey
Eli Lilly Stock Jumps 2.6% as Investors Flee Expensive Tech - TradingView
Eli Lilly (LLY) Stock Looks Undervalued Relative To Fair Value - simplywall.st
Inside Eli Lilly's Global CRM Partnership With Veeva - Healthcare Digital
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Genentech, two other drug companies object to Lilly's planned buyout of bankrupt Sangamo's tech - The Business Journals
Leal Therapeutics Closes $30M Series A Extension With Eli Lilly Investment - citybiz
Why Is Eli Lilly (NYSE:LLY) Drawing Attention after Its Strongest Quarter? - Kalkine Media
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):